Role of Xanthophylls in Visual Function

NCT ID: NCT05794074

Last Updated: 2023-03-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-01

Study Completion Date

2027-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ecy of lutein supplementation alone, or zeaxanthin supplementation alone, or a combination of both, compared to placebo, on the evolution of macular pigment density (MPOD) measured by fundus photography in XANTH-deficient patients receiving enteral nutrition.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lutein and zeaxanthin are plant pigments belonging to the carotenoid family, and more precisely to the subfamily of xanthophylls (XANTH), which are oxygenated carotenoids. These phytochemicals are not synthesised by humans and are almost always present in our diet. They are significantly absorbed and transported in our body. They are present in various organs, e.g. the eye and the skin. They accumulate in very high concentrations in the central area of the human retina. Because of this high accumulation, it has been hypothesised that they play one or more specific roles in the eye. This has been confirmed by several studies which have shown that XANTHs are involved in protecting the eye from damage by certain light rays (blue) and age-related macular degeneration. Other studies suggest that XANTH may improve glare tolerance and contrast sensitivity. They may also improve sensitivity to red and green colour discrimination. However, identifying the exact relationship between XANTH and visual function in XANTH supplementation is complicated by two main problems. Firstly, XANTH supplementation does not always increase MPOD (Macular Pigment Optical Density), which is an indicator of the concentration of XANTH in the macula, because there are poor responders to XANTH, i.e. subjects who absorb it very poorly and/or transport it very poorly to the retina. Secondly, MPOD seems to reach a maximum value and a plateau, and increasing the dose of XANTH, or the duration of supplementation, does not increase MPOD further. This is particularly the case in individuals who already have a high MPOD, close to the maximum value, before supplementation because they often consume XANTH-rich foods, and/or because they are strong responders to XANTH. Therefore, although studies suggest a specific role for XANTH in visual function, the problem of initially high MPOD in some individuals, coupled with MPOD saturation, has not allowed previous studies to provide definitive evidence on their role(s) in visual function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nutrition Deficiency (Xanth Deficiency) Due to A Particular Kind of Food

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

lutéine

10 mg/d lutéine

Group Type EXPERIMENTAL

luteine

Intervention Type DIETARY_SUPPLEMENT

luteine

zeaxanthine

10 mg/d zéaxanthine

Group Type EXPERIMENTAL

zeaxanthine

Intervention Type DIETARY_SUPPLEMENT

zeaxanthine

lutéine and zeaxanthine

10 mg/d lutéine + 2 mg/d zéaxanthine

Group Type EXPERIMENTAL

luteine and zeaxanthine

Intervention Type DIETARY_SUPPLEMENT

luteine and zeaxanthine

placebo

same excipient used in the other arms with a carmine red dye

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

luteine and zeaxanthine

luteine and zeaxanthine

Intervention Type DIETARY_SUPPLEMENT

luteine

luteine

Intervention Type DIETARY_SUPPLEMENT

zeaxanthine

zeaxanthine

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* On exclusive enteral nutrition for at least 6 months
* Exclusive enteral nutrition that is intended to be continued for at least 6 more months.
* No XANTH supplementation in the last 6 months.
* Able to sit up to allow visual examinations to be performed
* Sufficient understanding to perform visual examinations, at the discretion of the physician
* Written consent signed by the patient or agreement of their carer, trusted person, relative, family for patients with cognitive impairment (assessed using an MMS test). A patient with an MMSE test result ≤ 24 will be considered as having cognitive disorders.

Exclusion Criteria

* Current treatment with hydroxychloroquine or any other drug known to cause ocular toxicity
* Visually impaired patient: patient unable to read text (font size 11) at close range, with visual correction if the patient usually wears it
* Unoperated cataracts in both eyes
* Pregnant or breastfeeding woman
* Patient under legal protection: guardianship or curatorship
* Participation in other research in the same field of dietary supplementation, which may interfere with the results of this research.


* Absence of XANTH (lutein and zeaxanthin) deficiency\* in the blood sample taken at inclusion.
* Physical, ophthalmological or cognitive characteristics, evaluated at the Quinze-Vingt ophthalmological examination, which do not allow a reliable measurement of MPOD or of all the settings of visual function.
Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APHP220293

Identifier Type: -

Identifier Source: org_study_id